#United States #Franklin Lakes #Becton Dickinson #CentroVena One #Vizient Inc.

BD's Groundbreaking Recognition: CentroVena One™ Insertion System

BD (Becton, Dickinson and Company), a prominent player in the global medical technology field, recently celebrated a significant milestone with the awarding of an Innovative Technology contract for its CentroVena One™ Insertion System from
Vizient®, the leading provider in healthcare performance enhancement. This accolade acknowledges the product's potential to drive substantial advancements in healthcare delivery, specifically in the realm of central line insertion procedures.

The Recognition

The contract was bestowed following a rigorous evaluation by a council comprising hospital experts from Vizient. This assessment highlighted the CentroVena One™ system's unique capabilities, which set it apart from traditional methods. Its all-in-one design not only aims to boost clinical care but also places a strong emphasis on enhancing safety for both patients and clinicians, thereby streamlining procedural workflows.

Eric Borin, the worldwide president of BD's Medication Delivery Solutions, expressed pride in receiving this prestigious award, stating, "This recognizes the innovation behind CentroVena One™ and its potential to redefine how central lines are inserted. It validates the pressing clinical demand for a more straightforward and standardized approach to these procedures."

Innovations in Central Line Insertion

Central line insertion typically involves a series of intricate steps, often leading to risks of error, contamination, and procedural delays. The CentroVena One™ stands as a revolutionary solution—it's the first and only all-inclusive central venous catheter insertion system. Boasting an integrated design, it combines a guidewire, needle, syringe, and catheter into a single unit, simplifying the insertion process significantly. Studies indicate that it reduces the overall procedural steps by 30% and minimizes maximum procedure time by 50% when compared to conventional methods.

The design incorporates safety features aimed at lowering contamination risks and guarding against complications such as air and guidewire embolism, needlestick injuries, and clinician blood exposure. This innovative approach not only promises to enhance the consistency of procedures but also promotes more effective workflows across clinical settings.

Evaluating Worthiness

Kelly Flaharty, Associate Vice President of Contract Operations at Vizient, noted the decision to award BD with the contract following a thorough review process. "The CentroVena One™ Insertion System demonstrated a notable potential for differentiation in the competitive healthcare landscape, leading to our recommendation for the Innovative Technology contract."

Vizient represents a broad and diverse clientele, covering academic medical centers, pediatric facilities, community hospitals, along with non-acute healthcare providers, managing an impressive $156 billion portfolio in annual purchasing volume. Their Innovative Technology Program collaborates with client-led councils to assess products that can introduce true innovations in healthcare.

The Road Ahead

For BD, this recognition propels their mission of advancing health and innovation in medical technologies. With over 60,000 employees globally, BD is committed to developing transformative solutions that not only optimize clinical operations but also improve patient outcomes. By taking client needs into account, BD continues to strive for enhanced clinical efficiency and the expansion of healthcare access across regions.

For further insights on BD’s innovative offerings or to explore how they can support healthcare providers worldwide, visit bd.com or follow them on LinkedIn, Twitter, and Instagram.

Results derived from a head-to-head simulation study, with findings published in The Journal of Emergency Medicine, December 2025. Please note that results may not completely mirror actual clinical performance.